Fractionated-dose radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody (epratuzumab).: Interim results.

被引：0
|
作者：
Chatal, JF
Harousseau, JL
Truemper, LH
Meller, J
Pfreundschuh, M
Kirsch, CM
Naumann, R
Kropp, J
Wegener, WA
Ding, C
Horak, ID
Goldenberg, DM
机构：
[1] Inst Biol, INSERM, Res Unit 4, Nantes, France
[2] Ctr Hosp Univ, Serv Hematol, Nantes, France
[3] Univ Gottingen, D-3400 Gottingen, Germany
[4] Univ Saarland, Sch Med, Hamburg, Germany
[5] Univ Hosp Dresden, Dresden, Germany
[6] Immunomed Inc, Morris Plains, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1482
引用
收藏
页码：408A / 408A
页数：1
相关论文
共 50 条
  • [31] Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results
    Tomblyn, Michael B.
    Witzig, Thomas E.
    Himelstein, Andrew L.
    Elstrom, Rebecca
    Kio, Ebenezer A.
    Sharkey, Robert M.
    Rojo, Jonathan
    Wegener, William
    Goldenberg, David M.
    BLOOD, 2012, 120 (21)
  • [32] Therapy of refractory non-Hodgkin's lymphoma (NHL) with 131I-LL2 (anti-CD22) radioimmunotherapy (RIT):: Results of a repetitive dosing trial.
    Vose, J
    Colcher, D
    Bierman, P
    Gobar, L
    Hohenstein, M
    Augustine, S
    Goldenberg, D
    Tempero, M
    Armitage, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (01) : 65 - 65
  • [33] Therapy of refractory non-Hodgkin's lymphoma (NHL) with I-131-LL2 (anti-CD22) radioimmunotherapy (RIT): Results of a repetitive dosing trial.
    Vose, J
    Colcher, D
    Bierman, P
    Leichner, P
    Akabani, G
    Harrison, K
    Hohenstein, M
    Lesser, S
    Hammershaimb, L
    Goldenberg, DM
    Tempero, M
    Armitage, J
    BLOOD, 1996, 88 (10) : 2258 - 2258
  • [34] Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
    Witzig, Thomas E.
    Tomblyn, Michael B.
    Misleh, Jamal G.
    Kio, Ebenezer A.
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    HAEMATOLOGICA, 2014, 99 (11) : 1738 - 1745
  • [35] Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
    Juweid, ME
    Stadtmauer, E
    Hajjar, G
    Sharkey, RM
    Suleiman, S
    Luger, S
    Swayne, LC
    Alavi, A
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3292S - 3303S
  • [36] Positron Emission Tomography with F-18-fluorodeoxyglucose (PET-FDG) contributes to response evaluation of fractionated radioimmunotherapy (RIT) using 90Y-epratuzumab in non-Hodgkin's lymphoma (NHL).
    Bodet-Milin, C
    Ansquer, C
    Milpied, N
    Chatal, JF
    Wegener, WA
    Goldenberg, DM
    Kraeber-Bodéré, F
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S221 - S222
  • [37] Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy
    O'Donnell, Robert T.
    Pearson, David
    McKnight, Hayes C.
    Ma, Ya Peng
    Tuscano, Joseph M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (10) : 1715 - 1722
  • [38] Treatment of non-Hodgkin’s lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy
    Robert T. O’Donnell
    David Pearson
    Hayes C. McKnight
    Ya Peng Ma
    Joseph M. Tuscano
    Cancer Immunology, Immunotherapy, 2009, 58 : 1715 - 1722
  • [39] IDEC-Y2B8 (90)yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): Interim results of a Phase I/II trial.
    Witzig, T
    Wiseman, C
    White, CA
    Solinger, A
    Gordon, L
    Raubitschek, A
    Emmanoulides, C
    Royston, I
    Parker, E
    Chinn, P
    GrilloLopez, A
    BLOOD, 1997, 90 (10) : 2606 - 2606
  • [40] Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma
    Chinn, PC
    Leonard, JE
    Rosenberg, J
    Hanna, N
    Anderson, DR
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (05) : 1017 - 1025
12345